Injecting insulin can help treat chronic colitis

Image
ANI Washington D.C. [USA]
Last Updated : Sep 23 2018 | 12:25 PM IST

Not just diabetes, even chronic bowel inflammation can be treated effectively by injecting insulin into the rectum.

In a new study between departments at the University of Copenhagen and Roskilde University, researchers examined the effect of the treatment in a series of tests on mice with chronic colitis of the type Colitis Ulcerosa, among others.

The cause of these bowel disorders is unknown, but they cause patients great discomfort and can involve bloody diarrhea, anaemia, stomach ache, and weight loss.

Co-inventor of the treatment, Jørgen Olsen said, "Our new treatment with insulin on mice shows great potential against chronic bowel inflammation in humans like Colitis Ulcerosa, which causes a lot of people great discomfort. Existing treatments attack the bowel's immune system, dampening it; instead, our method strengthens the bowel cells' own defence. It appears to work equally well, and it can probably be used in combination with existing treatments."

The researchers have studied the effect of insulin treatment in various ways. First, they have shown that the amount of inflammation, expressed as the level of the marker Cox2, drops by 50 per cent compared to the saltwater control treatment.

Second, the researchers have measured the body weight of the mice - we know that people suffering from colitis typically lose a lot of weight because they do not eat much. As this marker is relatively crude, some studies of the existing treatment have shown no effect at all.

The insulin works because it activates a gene inside the bowel cells, which, according to other studies, has an antioxidant effect and thus may be able to protect the bowel cells from inflammation. This makes the new treatment different from existing medication, which instead of strengthening the bowel's defence weakens the immune system's attack on the bowel. And therefore the researchers hope the new treatment can be combined with the existing.

The full findings are present in the Journal of Crohn's and Colitis.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 23 2018 | 12:25 PM IST

Next Story